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ABSTRACT
Engaging global key opinion leaders, the Inter-
national Psoriasis Council (IPC) held a day-long
roundtable discussion with the primary purpose
to discuss the treatment goals of psoriasis
patients and worldwide barriers to optimal care.
Setting clear expectations might ultimately
encourage undertreated psoriasis patients to
seek care in an era in which great gains in
therapeutic efficacy have been achieved. Here,
we discuss the option for early treatment of all
categories of psoriasis to alleviate disease impact
while emphasizing the need for more focused
attention for psoriasis patients with mild and
moderate forms of this autoimmune disease. In
addition, we encourage policy changes to keep
pace with the innovative therapies and clinical
science and highlight the demand for greater
understanding of treatment barriers in resource-
poor countries.
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INTRODUCTION
Psoriasis is an immune-mediated inflammatory
skin disease with significant physical and psy-
chosocial consequences. Visible skin disfigure-
ment and the associated symptoms of itch,
pain, scaling, bleeding, burning, and cracking
have a significant impact on the patient’s
quality of life. Additionally, psoriasis is a sys-
temic disease with multiple comorbidities,
which increase the disease burden to beyond
the realm of the skin [1]. Despite the current
large inventory of effective treatment choices,
including innovative biologics and oral therapy,
undertreatment and non-treatment of psoriasis
is prevalent worldwide, including in Europe and
the USA [2]. This situation is even worse in
developing countries where psoriasis patients
with moderate-to-severe disease have poor
access to the novel and costlier therapies [2–6].
The ‘‘Clear about Psoriasis’’ global study
involving 31 countries (Western and non-Wes-
tern) identified that 57% of moderate-to-severe
psoriasis patients surveyed did not achieve
clear/almost clear skin on current therapy [7],
which recapitulates earlier findings that a
majority of psoriasis patients worldwide are
undertreated.
Key stakeholders agree that this global
problem is driven by economics, market access,
health policies, differences in the patient and
physician perspectives on the disease, knowl-
edge gaps, and the lack of established treatment
goals. Councilors from the International Psori-
asis Council (IPC) convened during a
roundtable event, with the primary purpose to
discuss clinical goals and specific barriers to
optimal treatment and to highlight challenges
for patients living in both Western and non-
Western countries (Table 1). The event included
dermatologists from ten different countries, and
the intent was to reveal global perspectives and
provide expert opinion.
This article does not contain any studies
with human participants or animals performed
by any of the authors.
CURRENT STATE OF PATIENT
SATISFACTION
In previous surveys psoriasis patients have
reported treatment dissatisfaction [2] and fail-
ure to meet treatment goals with current ther-
apy [3]. A recent review of 60 published studies/
articles, which included 35,388 psoriasis
patients, noted modest patient satisfaction,
with those patients treated with biologics
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reporting higher satisfaction than those treated
with oral therapies, phototherapy, or topicals
[8]. How these data would differ today given the
introduction of the newer biologic therapies,
such as interleukin (IL) inhibitors (IL-17 and IL-
23), which have excellent clinical efficacy but
significant cost issues, is yet to be determined.
Part of the problem is that the majority of
recent innovation have been targeted to the
moderate-to-severe patient population, with
little new successful development for those
psoriasis patients with mild and moderate
disease.
Psoriasis severity is generally defined by
clinicians using objective measures of body
surface area (BSA), the Psoriasis Area Severity
Index (PASI), or one of several Physician Global
Assessment (PGA) measures [9]. Additionally,
the impact of psoriasis on patients’ quality of
life may be evaluated by the Dermatology Life
Quality Index (DLQI), a self-reported question-
naire assessing the physical, psychological, and
social well-being of patients [10]. Psoriasis
patients and their physicians differ with regard
to which psoriasis symptoms are most impor-
tant. For example, some patients have found
itch to be most bothersome, while dermatolo-
gists reported the location and size of the skin
lesions as paramount [11]. Itch, affecting
60–96% of patients, is the primary source of
discomfort, negatively impacting daily physical
and mental well-being [12–14]. Clinical studies
with ixekizumab [15, 16], tofacitinib [17],
apremilast [18], etanercept [19], and secuk-
inumab [20] have shown a significant associa-
tion of improvement of itch with a correlative
improvement of the quality of life for patients.
Not surprisingly, the reduction of itch and pain
is strongly correlated with skin clearance [21]
[15]. In addition to physical symptoms of itch
and pain, the visible aspect of the disease
impacts many psychosocial domains. Anxiety
and depression can lead to avoidance and
reduction of social interactions [7, 22, 23]. In a
recent global study, 84% of psoriasis patients
surveyed reported humiliation, discrimination,
difficulty in social/work situations, sleep dis-
turbance, and mental health issues. In addition,
both the physical symptoms plus psychiatric
morbidity can negatively impact intimate rela-
tionships and sexual activity [24, 25]. These
important factors, if recognized by the derma-
tologist, can be used to guide treatment deci-
sions and provide educational health resources
to the patient.
The reason for the discrepancy between
patients and physician regarding the most
bothersome symptoms of the disease is possibly
due to the objective approach taken to deter-
mine disease severity by the physician versus
the subjective manner by which patients expe-
rience and monitor their disease symptoms.
Consequently, the physician’s use of the PASI
could potentially miss the effect of a therapy on
Table 1 Approaches to advance psoriasis care worldwide
Approaches to advance global psoriasis care
Treatment goal: total skin clearance and reduction of symptoms (most importantly itch) are important to the patient
(objective tool ? psoriasis-specific PRO to assess symptom severity = impact of disease)
Early treatment with effective therapy; reduction in time to initiation of biologic or new oral therapies
Encourage policy changes to keep pace with innovative therapies and clinical science
Advocate and treat psoriasis as a lifelong, systemic inflammatory disease, incorporating comorbidity screening
Deeper understanding of unmet needs in countries outside of Europe and North America; need for realistic yet effective
national treatment programs
Greater focus is needed on treatment of mild to moderate disease patients that do not meet criteria for biologics or new
oral therapies
PRO Patient reported outcome
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the specific symptoms, such as itch, burning,
pain, and stinging, that commonly affect pso-
riasis patients. The DLQI captures the symp-
toms of itching, soreness, pain, and stinging
using one question, but it does not evaluate
each separately. This points to the potential
value of utilizing psoriasis-specific patient-re-
ported instruments that assess individual
symptoms in conjunction with quality-of-life
inquiries.
DISEASE-SPECIFIC PATIENT
REPORTED OUTCOME MEASURES
ARE NEEDED TO DEFINE SUCCESS
AND TO INFORM CLINICAL
DECISIONS
Current outcome measures may not be helpful
in distinguishing which psoriasis therapies are
clinically meaningful unless they have estab-
lished the minimal clinically important differ-
ence (MCID) for score change [26]. Certainly,
the main goal of psoriasis treatment is to
achieve skin clearance and to restore the
patient’s normal daily activities to where this
disabling disease has no impact on work, family
life, social connections, and well-being of the
patient [7, 26].
To this end, patient reported outcomes
(PROs) complement and qualify objective (ob-
server only) tools [26, 27] and move the focus
from objective to subjective (patient-experi-
enced) measures. The DLQI, a PRO that is not
specific for psoriasis, is composed of content
that includes important and relevant concepts
from the perspective of psoriasis patients [28]
and is the most widely accepted PRO currently
available to clinicians. Psoriasis-specific PROs
should capture corresponding elements of the
DLQI that have been clinically validated, that
are responsive to change, and which are deter-
mined as well understood by patients [28, 29]
but which may need to be expanded to include
other elements. A thorough assessment of pso-
riasis-specific PRO tools has been systematically
reviewed elsewhere [30, 31].
The International Dermatology Outcome
Measures Group (IDEOM) is one initiative
which aims to establish validated and stan-
dardized outcome measures that satisfy the
needs of all stakeholders for use in clinical trials
and clinical practice [32–34]. The core domains
that have been identified are skin manifesta-
tions (surface area of involvement, location,
redness, induration, and scale), investigator
global assessments, psoriasis and psoriatic
arthritis symptoms, patient global assessment,
treatment satisfaction, and health-related qual-
ity of life [35].
Ideally, an effective PRO with regard to
measuring both disease severity and treatment
effects could replace objective metrics such as
the PASI or PGA. Furthermore, the discussion of
PRO results has the potential to significantly
enhance the physician–patient interaction and
contribute to the formation of valid treatment
goals.
TREATMENT EXPECTATIONS
AND CLINICAL GOALS
In the majority of cases, patient expectations
are influenced by the clinician, but neither the
patient nor the clinician may be fully aware of
what the patient believes is most important.
Dermatologists are generally calibrated to
patient expectations that are highly related to
factors such as age, gender, socioeconomic sta-
tus, occupation, and geographic locale [36]. In a
German registry, patients surveyed reported a
wide range of highly valued treatment goals
beyond skin clearance, which included
improvement of itching, burning, and pain and
normal life functioning [37]. In addition, many
patients are unaware that there is a possibility of
attaining 100% clearance over both the short
term and long term, or of achieving substantial
improvement or elimination of their most
troublesome symptoms [7]. Treatment goal
misalignment was reported in 67.9% of
patient–physician pairs surveyed in a study
conducted in Japan which examined skin
clearance as a goal indicator [38]. The main
reason for misalignment was that patients
expressed a higher goal than physicians. This
finding again highlights the importance of
dermatologists recognizing patient expectations
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in order to reach clinical goals. It is likely that
this disconnect also contributes to the finding
that adherence to treatment falls well below
that for other chronic conditions [39, 40]. In
part, adherence is negatively affected by patient
psychological barriers related to past failed
treatments, whereby the patient becomes
resigned to modest or limited outcomes (inad-
equate skin clearance and relief from symp-
toms) [41].
WHAT DEFINES TREATMENT
SUCCESS OR FAILURE?
Treatment success in managing chronic disease
has been defined as control of a target that is
quantifiable to a specified value or range (e.g.,
for certain conditions, glycated hemoglobin
levels, lipid profiles, blood pressure ranges, or
virus burden). The identification and accep-
tance of treatment goals require the establish-
ment of minimal disease criteria through
literature review and a subsequent expert con-
sensus building exercise, such as the Delphi
process. Target goals should be defined for both
the initiation and maintenance phases of
treatment and should also be easy to implement
in clinical practice and feasible to attain. Ide-
ally, treatment goals should correlate with
meaningful effects on systemic comorbidities,
such that achieving these targets has positive
effects on either morbidity or mortality. Such
targets for psoriasis therapy are yet to be
identified.
Once target goals have been established, a
‘‘treat to target’’ approach can be compared to
standard care to identify the best approach for
disease management. For example, in psoriatic
arthritis, the Tight Control of Psoriatic Arthritis
study (TICOPA) investigated an intensive and
early treatment protocol versus standard care
[42]. First, the target goals of minimal disease
activity (MDA) criteria were validated through
observation and investigational studies and
then these goals were applied in the TICOPA
study. The results of the study determined that
intensive care (review every 4 weeks, with esca-
lation of treatment to MDA targets) provided
greater patient improvement in disease activity
and reduction in joint damage than standard
care (review at 12 weeks).
Treatment goals for psoriasis have been
defined by European [43], American [44],
Canadian [45], and Australian [46] consensus
committees according to shared criteria that
define treatment success. The recently pub-
lished consensus from the US National Psoriasis
Foundation posits that an acceptable response
to treatment at 3 months after initiation is B 3%
BSA or a BSA improvement of C 75% from
baseline; the target treatment response at
3 months after initiation is B 1% BSA; and the
target response at each 6-month maintenance
appointment is B 1% BSA [44].
These targets, which have been established
to improve patient outcomes in diverse clinical
settings within Western countries, may need
modification in non-Western countries due to
safety concerns in vulnerable populations. For
example, Brazil has adopted the European tar-
gets with a few modifications due to the high
local prevalence of human T-lymphotropic
virus (HTLV) and tuberculosis infection burden,
which demands screening before initiating
treatment with immunosuppressive therapies
[47]. More information is needed to establish
the burden of psoriasis within populations of
Latin America and the Caribbean in order to
gain a stronger understanding of patient per-
spectives and barriers to care [48].
The Malaysian Ministry of Health lists treat-
ment goals as minimum targets within therapy
categories (topicals, phototherapy, conven-
tional therapies, or biologics) and highlights the
need for target goals to be based on patient
severity and patient preference [49].
CLINICALLY MEANINGFUL
TARGETS
It appears to be relatively straightforward to
provide treatment with the target of skin clear-
ance based on BSA, PASI, or PGA (minimal dis-
ease criteria), but the degree that is clinically
meaningful to the patient should be clarified. A
recent study examined the impact of total skin
clearance on quality of life from the patient’s
perspective by investigating PSI and DLQI [26].
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Patients that responded to treatment with total
skin clearance (PASI 100 and PGA 0) demon-
strated minimal or no impairment in derma-
tology-related quality of life factors or signs and
did not experience symptoms of psoriasis. This
outcome translates into a clinically meaningful
treatment goal for patients. The study further
revealed that even small areas of residual disease
in patients that did not respond with complete
clearance have a negative impact on patient
quality of life and psoriasis symptoms.
Examination of other target goals below
PASI100 might also be useful for determining
the relationship between categories of PASI
response levels. For example, data derived from
clinical studies on secukinumab reveal that
achieving a PASI response of 90 correlates with
better quality of life (DLQI 0/1) at week 12 than
achieving a PASI response of 75–89 [50]. When
setting treatment goals, it should be understood
that the concept of percentage PASI reduction
as the only outcome measure might not be rel-
evant for individual patients; rather, absolute
change is usually more relevant. In this vein,
the MCID score for absolute change of the
metric being used should be better understood;
for example, for the DLQI, the MCID is a score
change of 4 [51].
Overall, current evidence supports the con-
clusion that greater skin clearance correlates
with greater improvement of patient quality of
life. However, studies have also shown that skin
lesion severity on the head and upper extremi-
ties had disproportionately large impacts on
DLQI compared with BSA, particularly for
younger women and men. The impact was sig-
nificantly greater in women aged \45 years
(higher DLQI) [52]. In addition, genital psoria-
sis, which affects over 60% of psoriasis patients,
imparts significant impairment on the quality
of life, feelings of stigmatization, and impact on
sexual health [25]. These findings again point to
the importance of patient perspectives on
treatment goals and expectations.
Finally, the impact of psoriasis extends
beyond the patient. Disease burden on family
members and partners has garnered little
attention in the past and, due to this lack of
consideration, is a hidden and often ignored
important aspect of the disease. However,
observational studies have captured the degree
of impairment in the quality of life of persons
living with psoriasis patients using family
quality reported outcome instruments, such as
Psoriasis Family Index (PFI), Family Dermatol-
ogy Life Quality Index (FDLQI), and Family
Reported Outcome Measure (FROM-16)
[23, 53–56]. Family members are burdened with
psychological pressures, disruption of social,
holiday, and sports activities, and disturbance
in daily activities [23].
TREAT-TO-TARGET: A REALITY
OR ASPIRATIONAL?
The treat-to-target approach may be difficult to
implement in global clinical practices if the
target goal is too ambitious and beyond the
reach of the majority of patients. PASI100
should be considered to be an aspirational and
important goal, as no current treatment can
achieve it in more than 50% of patients. For
example, in the UNCOVER-1 study, 35.3% of
patients treated with ixekizumab reached
PASI100 at week 12 [57]. PASI 90, on the other
hand, is achievable in a larger percentage of
patients treated with IL-17 inhibitors (ixek-
izumab 70.9% [57]; secukinumab 70.0% [58];
brodalumab 70.3% [59]) and IL-23p19 inhibi-
tors (risankizumab 77% [60]; tildrakizumab 58%
[61]; guselkumab 73.3% [62]). Other concerns
regarding the treat-to-target approach include
the possibility of inappropriate treatment if
non-response or loss of response is not well
understood, patient reluctance to undergo
increased monitoring, dosing, or switching of
therapies with a different mode of action, and
potential increase in cost. Ultimately, therapy
must be customized, as the definition of success
will depend on the patient’s perspective [63].
In addition, goals should be set to encourage
physicians to optimize treatments and maxi-
mize long-term quality of life—while reducing
the risk of important comorbidities. However,
setting an actual number value within formal
treatment guidelines used by physicians and
private healthcare insurers may negatively
impact access. For example, if a target is not met
despite the patient being satisfied, insurers
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might deny payment. In resource-poor coun-
tries, such as Brazil, where the government
health agencies approve biologics but deny
access to the public healthcare system due to
economic reasons, physicians would be caught
between the treat-to-target guidelines (and
patient expectations) and divergent public
healthcare policies [47].
CLEARANCE AND LONGEVITY
With the current broad spectrum of available
psoriasis therapies, sustained and consistent
clearance of psoriasis is a definite possibility
[26]. In large patient populations, greater
clearance translates to greater satisfaction, as
patients who achieve full clearance (when
compared to those who are ‘‘almost clear’’) more
often report greater symptom resolution [64].
Importantly, psoriasis patients who are effec-
tively treated may display a ‘‘reset’’ of the level
of disease that can be tolerated. Treatment dis-
continuation after initial success results in a
rebound dissatisfaction with returning disease
(worsening of quality of life). Small recurrences
of psoriasis therefore translate into dispropor-
tionately larger detrimental effects on quality of
life reporting [65]. Reduction of drug dose after
initial treatment success could result in a similar
phenomenon [66].
These data would support the avoidance of
unnecessary switching among therapies in
order to increase the likelihood of long-term
patient satisfaction. However, sustained efficacy
is still a significant shortcoming with the bio-
logic therapies, and corrective approaches to
this problem are hindered by a lack of head-to-
head studies between therapies and an under-
standing of the mechanisms by which therapies
lose their effectiveness over time. Access to
observational prospective registries has allowed
some comparative assessments of long-term
efficacy [67–69]. The use of concomitant
immunomodulatory drugs, such as methotrex-
ate, is inadequately studied, but it is well rec-
ognized from the rheumatology literature that
this approach may lengthen treatment response
[70, 71]. In this regard, it is important to realize
that only monotherapy (including no potent
topical steroids) is allowed in psoriasis clinical
trials, whereas in rheumatology clinical studies,
including those in psoriatic arthritis, more than
50% of patients in the clinical trials conducted
to date are on concomitant systemic therapy
(methotrexate, prednisone, etc.). In addition,
because drug durability rates are possibly lower
in the clinical setting than in controlled trials,
more real-world studies [72] are needed to gauge
the longevity of response of the novel biologics
and oral therapies.
There is also a need for variable dosing in
studies of the various drugs to better understand
how long-term clearance might be sustained.
Internationally, methotrexate is the most
widely used systemic therapy due to its reason-
able efficacy and low cost. A recent survey
administered across 63 countries demonstrated
significant differences on dosing, route of
administration, and safety monitoring of
methotrexate [73]. In fact, an intensified dosing
schedule of subcutaneous methotrexate over
52 weeks was found to be effective and well
tolerated in moderate to severe patients [74].
CLINICAL INERTIA AND PATIENT
BARRIERS
Clinical inertia, a concept coined in early 2000s,
is defined as the failure to initiate and/or to
intensify care when treatment goals are not met
[75]. Evidence for clinical inertia in the treat-
ment of psoriasis has been established; for
example, in the studies (described above) in
which only 31% of patients report that the
target goal of skin clearance is reached.
Recent observational evidence suggests that
patients, on average, seek referral to a secondary
care (specialist) 15 years after presentation [76].
The authors of this study report that this delay
in seeking help can be attributed to several
barriers, including familial experience of the
disease (acceptance that many family members
have psoriasis); previous failed therapies and
thus a sense of hopelessness; lack of follow-up
to assess treatment response after initiation; and
difficulty in obtaining a secondary care referral.
Strikingly, patient conception of psoriasis as
being neither curable nor life-threatening, and
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thus unworthy of treatment, was also identified
as a strong barrier to seeking effective treatment
[76]. The barriers identified here are modifiable
and have the potential to lead the patient to
early treatment.
Access to expert care for patients with mod-
erate to severe disease is affected by several
factors. First among these is the inadequate
supply of or limited access to dermatology
practitioners in countries worldwide. Second,
the framework in which patients receive care
may not support the complexity needed for
appropriate evaluation and management of
psoriasis. Given the time constraints of the
average dermatology clinic visit (5–15 min),
arriving at effective treatment that maximizes
both physician and patient outcomes and sat-
isfaction may be challenging. Third, access to
medications is frequently constrained. While
psoriasis is a systemic disease associated with
chronic inflammation and, in a number of
patients, end-organ damage, it continues to be
viewed by patients, physicians, and payors as a
cosmetic or ‘‘itchy skin’’ problem and not of
equal health significance as, for example,
rheumatologic disorders. For example, US pay-
ers make decisions on physician and drug
quality based on claims databases in commu-
nity practices that do not assess either patient
severity, associated comorbidities, or disease-
specific outcomes [77]. Treatment regimens for
psoriasis patients should be tailored to meet
specific needs based on disease severity, impact
on quality of life, response to previous thera-
pies, and presence of comorbidities. With regard
to comorbidities such as psoriatic arthritis, it is
important to ensure that the appropriate agent
not only improves the disease symptoms but
also has the potential to inhibit the radio-
graphic progression of disease [78]. In addition,
since psoriasis is a chronic systemic and incur-
able disease that affects all age groups, special
populations, such as pregnant women, pediatric
patients, elderly patients, and those with
chronic infections, must be considered [79].
Disparate treatment access for psoriasis
patients is especially high for those who seek
biologic treatment and new oral therapies in
developing countries. In 2016, the World
Health Organization issued a global report to
emphasize that psoriasis is a serious, disfiguring,
and disabling non-communicable disease and
set forth actions to improve healthcare across
all countries [6]. Communicable diseases still
contribute significantly to disease burden in
most developing countries, and a majority of
the financial resources is dedicated to providing
these treatments. However, recent studies have
reported that the occurrence of non-communi-
cable disease doubles the overall health burden
[80, 81]. In some developing countries the eco-
nomic burden of modern, highly effective
therapies will drive the discussion. Unless
pharmaceutical companies, payers, and regula-
tors reach a consensus on how to adequately fit
treat-to-target guidelines into the healthcare
general budget, achieving excellent standard of
care will be challenging. A better understanding
of factors that influence disparity is critical to
narrowing the healthcare gaps for patients.
CONCLUSIONS
Over 125 million people living with psoriasis
depend on feasible approaches to attain treat-
ment goals in order to reverse the current state
of untreated and undertreated patient popula-
tions. Delivering comprehensive treatment
information to the patient will help develop
realistic expectations and lead to improved
health outcomes [36, 43]. Further, patients and
healthcare providers should appreciate that
even though skin clearance is achieved in the
short term, clearance must be maintained and a
long-term strategy must be implemented in the
form of a multidisciplinary approach that limits
the comorbidities associated with psoriasis
[11, 82, 83].
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